Podstawowe statystyki
| CIK | 883107 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Solesence, Inc.
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-42589 Solésence, Inc. (Ex |
|
| May 12, 2026 |
EXHIBIT 99.1 Solésence Reports First Quarter 2026 Financial Results Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announ |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-42589 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2026 (April 24, 2026) SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 29, 2026 |
EXHIBIT 99.1 Solésence, Inc. Announces Appointment of New Independent Director Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc |
|
| April 23, 2026 |
NANOPHASE TECHNOLOGIES CORPORATION (the “Company”) CLAWBACK POLICY SOLÉSENCE, INC. 10-K/A Exhibit 97.1 NANOPHASE TECHNOLOGIES CORPORATION (the “Company”) CLAWBACK POLICY Introduction The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's pay-for-performance compensation philosoph |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-42589 SOLÉSE |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-42589 SOLÉSENCE, INC. (Exact nam |
|
| March 31, 2026 |
EXHIBIT 99.1 Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 20 |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 31, 2026 |
SUBSIDIARY OF SOLÉSENCE, INC. (as of December 31, 2025) SOLÉSENCE, INC. 10-K Exhibit 21.1 SUBSIDIARY OF SOLÉSENCE, INC. (as of December 31, 2025) Name Jurisdiction of Formation Solésence, LLC Delaware |
|
| December 3, 2025 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release is made between Solésence, Inc. f/k/a Nanophase Technologies Corporation, a Delaware corporation (with its subsidiaries, successors, and assigns, referred to as “SLSN” or the “Company”), and Jess Jankowski (the “Agreement”). Mr. Jankowski and SLSN are, collectively, the “Parties” to this Agreement. THIS IS A LEGALL |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (November 24, 2025) SOLESENCE, INC (Exact name ofregistrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 (November 21, 2025) SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) |
|
| December 1, 2025 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is made on November 22, 2025 between Solésence, Inc., a Delaware corporation, with its corporate offices in Romeoville, Illinois (“SLSN” or “Company”) and Jess Jankowski, a sole proprietor with his offices in Elkhorn, Wisconsin (“Consultant”). 1. Consulting Services. Consultant will use his experience and expertise, acquired |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2025 |
Solésence Third Quarter 2025 Financial Results Conference Call Outline EdgarFiling Exhibit 99.2 Solésence Third Quarter 2025 Financial Results Conference Call Outline Operator Good day. Thank you for standing by. Welcome to the Solésence third quarter 2025 conference call. [Operator Instructions] Today's call is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, |
|
| November 13, 2025 |
EXHIBIT 99.1 Solésence Reports Third Quarter 2025 Financial Results Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for t |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Solésence, I |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 (October 31, 2025) SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) ( |
|
| November 6, 2025 |
CONFIDENTIAL SETTLEMENT AGREEMENT & RELEASE SOLESÉNCE, INC. 8-K Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT & RELEASE This Confidential Settlement Agreement and Release (the “Settlement Agreement”) is entered into by and between: (1) Solésence, Inc., including its subsidiary, Solésence, LLC (collectively, “Solésence”), and (2) Solarium Brands, LLC and A-Frame Brands, LLC (collectively, “Solarium”). (Solésence and Solarium are each refere |
|
| September 4, 2025 |
TRANSITION EMPLOYMENT AGREEMENT Solésence, Inc. 8-K Exhibit 10.2 TRANSITION EMPLOYMENT AGREEMENT This Transition Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), is made between Solésence, Inc. f/k/a Nanophase Technologies Corporation, a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Jess Jankowski (“Mr. Jankowski”). Preliminary Statement Mr. Jankowsk |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Num |
|
| September 4, 2025 |
Solésence, Inc. 8-K Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), is made between Solésence, Inc. f/k/a Nanophase Technologies Corporation, a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Kevin Cureton (“Mr. Cureton”). Preliminary Statement Mr. Cureton has been continuously emp |
|
| September 4, 2025 |
Solésence, Inc. 8-K Exhibit 99.1 Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth Strategic transformation of Solésence continues with Kevin Cureton promoted to President and Chief Executive Officer; Laura Riffner named Chief Financial Officer; Jess Jankowski to serve as Board Advisor Romeoville, Ill., September 3, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leade |
|
| September 4, 2025 |
Solésence, Inc. 8-K Exhibit 10.3 EMPLOYMENT AGREEMENT This Amended Employment Agreement dated and effective as of September 3, 2025 (this “Agreement”), between SOLESENCE, INC., a Delaware corporation (with its successors and assigns, referred to as the “Company”), and Laura Riffner, (referred to as Employee”). Preliminary Statement The Company desires to employ Employee, and Employee wishes to be |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Numbe |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Solésence, Inc. ( |
|
| July 31, 2025 |
EXHIBIT 99.1 Solésence Reports Second Quarter 2025 Financial Results Strong commercial execution drove revenue growth of 56% to $20.4 million ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025 |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 9, 2025 |
SOLESENCE, INC 8-K Exhibit 3.1 Delaware Page 1 The First State I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CORRECTION OF “SOLESENCE, INC.”, FILED IN THIS OFFICE ON THE THIRD DAY OF JUNE, A.D. 2025, AT 4:35 O`CLOCK P.M. 2820214 8100 Authentication: 203861879 SR# 20252963635 Date |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 SOLÉSENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-42589 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-42589 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number |
|
| June 2, 2025 |
Solésence Expands Debt Facilities to Fuel Growth Initiatives Solesence, Inc. 8-K Exhibit 99.1 Solésence Expands Debt Facilities to Fuel Growth Initiatives Romeoville, Ill., June 2, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to sup |
|
| June 2, 2025 |
A/R Loan Agreement Amendment, dated May 27, 2025. Solesence, Inc. 8-K Exhibit 10.2 THIRD AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC., a Delaware corporation (F/K/A NANOPHASE TECHNOLOGIES CORPORATION) (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan A |
|
| June 2, 2025 |
Term Loan Agreement Amendment, dated May 27, 2025. Solesence, Inc. 8-K Exhibit 10.1 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC. (f/k/a NANOPHASE TECHNOLOGIES CORPORATION), a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 |
|
| June 2, 2025 |
Revolving Loan Agreement Amendment, dated May 27, 2025. Solesence, Inc. 8-K Exhibit 10.3 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of May 27, 2025 and is by and between SOLÉSENCE, INC., a Delaware corporation (F/K/A NANOPHASE TECHNOLOGIES CORPORATION) (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( as |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Solesence, Inc. |
|
| May 7, 2025 |
Exhibit 99.1 Solésence Reports Record First Quarter 2025 Financial Results First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Rece |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 7, 2025 |
Solésence First Quarter 2025 Conference Call Script EdgarFiling Exhibit 99.2 Solésence First Quarter 2025 Conference Call Script Operator Introduction Good day. Thank you for standing by. Welcome to the Solésence first quarter 2025 conference call. [Operator Instructions] Today's call is being recorded. During this call, management will make statements that include forward-looking statements within the meaning of the federal securities laws, which |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Solesence, Inc. (Exact name of registrant as specified in its charter) Delaware 36-3687863 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 1319 Marquette Drive |
|
| April 7, 2025 |
EXHIBIT 99.1 Solésence Announces Uplisting to Nasdaq Trading set to begin Tuesday, April 8 under new ticker “SLSN” ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to t |
|
| April 7, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 7, 2025 |
The Nasdaq Stock Market LLC, 1100 New York Ave. NW, Suite 310E, Washington, DC 20005 Eun Ah Choi Senior Vice President Global Head of Regulatory Operations April 7, 2025 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on April 7, 2025 The Nasdaq Stock Market (the "Exchange") r |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 SOLESENCE, INC. (Exact nam |
|
| March 31, 2025 |
SUBSIDIARY OF SOLESENCE INC. (as of December 31, 2024) Solesence, Inc. 10-K Exhibit 21.1 SUBSIDIARY OF SOLESENCE INC. (as of December 31, 2024) Name Jurisdiction of Formation Solésence, LLC Delaware |
|
| March 31, 2025 |
Solesence, Inc. 10-K Exhibit 19 Solésence, Inc. 1319 Marquette Drive Romeoville, Illinois 60446 TO: All Directors, Advisory Board Members, Officers and Employees of Solésence FROM: Insider Trading Compliance Officer, Jess Jankowski DATE: March 7, 2025 RE: Amended Policy on Insider Trading In the course of employment or other relationship with Solésence, Inc. (“Solésence” or the “Company”), directo |
|
| March 26, 2025 |
EXHIBIT 99.1 Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) - Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, to |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 SOLESENCE, INC. (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employer jurisdiction of File Number |
|
| March 12, 2025 |
Certificate of Amendment to the Company’s Certificate of Incorporation, filed March 10, 2025. Exhibit 3.1 |
|
| January 16, 2025 |
Nanophase Technologies Corporation 8-K Nanophase Technologies Corporation 8-K Exhibit 3.1 |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Com |
|
| December 26, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te |
|
| October 30, 2024 |
Nanophase Reports Record Third Quarter Revenue and Profit EXHIBIT 99.1 Nanophase Reports Record Third Quarter Revenue and Profit —Nanophase Reports Q3 Revenue Record at $16.9 Million with Solésence Revenue up 171% YOY —Record $3 Million in Q3 Profit ROMEOVILLE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science c |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 20) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 5215 Old Orchard Road, Suite 620 Skokie, Illinois 60077 Telephone: (847) 733-1230 (Name, Addre |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| August 6, 2024 |
Nanophase Reports Record Second Quarter Revenue and Profit EXHIBIT 99.1 Nanophase Reports Record Second Quarter Revenue and Profit —$13 Million in Q2 Revenue, with Solésence Revenue up 44% YOY —$1.7 Million in Profit for the First Half of 2024 alongside Record Q2 Profit —Record Third Win in a Row at Cosmoprof and Cosmopack North America ROMEOVILLE, Ill., Aug. 06, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral |
|
| June 26, 2024 |
SC 13D/A 1 nan3d20.txt SCHEDULE 13D AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 19) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 5215 Old Orchard Road, Suite 620 Skokie, Illinoi |
|
| May 31, 2024 |
United States securities and exchange commission logo May 31, 2024 Jess Jankowski President NANOPHASE TECHNOLOGIES Corp 1319 Marquette Drive Romeoville , Illinois 60446 Re: NANOPHASE TECHNOLOGIES Corp Form 10-K filed March 28, 2024 File No. |
|
| May 31, 2024 |
SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 29, 2024 |
May 24, 2024 Securities and Exchange Commission Division of Corporate Finance 100F Street, NE Washington, DC 20549 Attn: Mr. |
|
| May 21, 2024 |
SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno |
|
| April 23, 2024 |
Nanophase Reports Record First Quarter Results EXHIBIT 99.1 Nanophase Reports Record First Quarter Results — Delivered $9.9 Million in Q1 Revenue — $0.9 Million in Profit — BASF Litigation Resolved ROMEOVILLE, Ill., April 23, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect |
|
| April 23, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| April 12, 2024 |
United States securities and exchange commission logo April 12, 2024 Jess Jankowski President NANOPHASE TECHNOLOGIES Corp 1319 Marquette Drive Romeoville , Illinois 60446 Re: NANOPHASE TECHNOLOGIES Corp Form 10-K filed March 28, 2024 File No. |
|
| April 11, 2024 |
SETTLEMENT AGREEMENT AND GENERAL RELEASE Exhibit 99.2 SETTLEMENT AGREEMENT AND GENERAL RELEASE This Settlement Agreement and General Release (“Agreement”) is made and entered into by and between BASF Corp. (“BASF”) and Nanophase Technologies Corp. (“Nanophase”) (as defined herein) (each a “Party,” and collectively, the “Parties”). WHEREAS, BASF filed the Lawsuit against Nanophase arising from the Parties’ Zinc Oxide Supply Agreement, ame |
|
| April 11, 2024 |
EXHIBIT 10.1 AMENDMENT NO. 5 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 5 (“Amendment No. 5”) to the Zinc Oxide Supply Agreement is entered into as of April 10, 2024, (“Amendment No. 5 Effective Date”) and is made by and between BASF CORPORATION, a Delaware corporation (“BASF” or “Purchaser”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). Nanophase and BASF ar |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of i |
|
| April 11, 2024 |
Nanophase Announces Successful Litigation Settlement EXHIBIT 99.1 Nanophase Announces Successful Litigation Settlement ROMEOVILLE, Ill., April 11, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — announced today |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| March 28, 2024 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2023) NANOPHASE TECHNOLOGIES CORPORATION 10-K EXHIBIT 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2023) Name Jurisdiction of Formation Solésence, LLC Delaware |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| March 21, 2024 |
Nanophase Reports Fourth Quarter and Year End 2023 Results, New Financing Package EXHIBIT 99.1 Nanophase Reports Fourth Quarter and Year End 2023 Results, New Financing Package — Delivered $37.3 million in full year revenue — Closed on $6 million financing — Won 2024 Cosmetics and Toiletries Allē Award Finished Formula Prestige Category ROMEOVILLE, Ill., March 20, 2024 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientific |
|
| March 5, 2024 |
Term Loan Agreement Amendment, dated March 1, 2024. Nanophase Technologies Corporation 8-K Exhibit 10.2 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 (a |
|
| March 5, 2024 |
SC 13D/A 1 nan3d19.txt SCHEDULE 13D AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 18) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 5215 Old Orchard Road, Suite 620 Skokie, Illinoi |
|
| March 5, 2024 |
Securities Purchase Agreement, dated March 1, 2024. Nanophase Technologies Corporation 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (“Agreement”) dated as of March 1, 2024 by and between STRANDLER, LLC, a South Dakota limited liability company (“Purchaser”), and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Company, and its subsidiary, SOLÉSENCE, LLC, a |
|
| March 5, 2024 |
NANOPHASE ANNOUNCES $6M FINANCING Nanophase Technologies Corporation 8-K Exhibit 99.1 Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, IL 60446 NANOPHASE ANNOUNCES $6M FINANCING Romeoville, Ill., March 5, 2024 – Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin |
|
| March 5, 2024 |
Revolving Loan Agreement Amendment, dated March 1, 2024. Nanophase Technologies Corporation 8-K Exhibit 10.4 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 (as am |
|
| March 5, 2024 |
A&R Loan Agreement Amendment, dated March 1, 2024 Nanophase Technologies Corporation 8-K Exhibit 10.3 SECOND AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This Second Amendment is dated as of March 1, 2024 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan Agr |
|
| March 5, 2024 |
Certificate of Designations, filed March 4, 2024. Nanophase Technologies Corporation 8-K Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of SERIES X PREFERRED STOCK of NANOPHASE TECHNOLOGIES CORPORATION (Pursuant to Section 151 of the Delaware General Corporation Law) NANOPHASE TECHNOLOGIES CORPORATION, a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called the "Company"), hereby certifies that |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Com |
|
| February 12, 2024 |
SC 13D/A 1 nan3d18.txt SCHEDULE 13D AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 17) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 5215 Old Orchard Road, Suite 620 Skokie, Illinoi |
|
| December 20, 2023 |
Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, Illinois 60446 (630) 771-6708 December 19, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| December 19, 2023 |
As filed with the Securities and Exchange Commission on December 19, 2023 As filed with the Securities and Exchange Commission on December 19, 2023 Registration No. |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 99.2 FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 Dear Stockholder: Enclosed are materials relating to a rights offering by Nan |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 4.11 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS (THE “PROSPECTUS”) WHICH FORMS A PART OF THE REGISTRATION STATEMENT ORIGINALLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 21, 2023, AS AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PRO |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 99.3 FORM OF LETTER TO NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 To Securities Dealers, Commercial Banks, Trust Companies and Other Nominees: This letter is being |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 99.4 FORM OF LETTER TO CLIENTS OF NOMINEE HOLDERS NANOPHASE TECHNOLOGIES CORPORATION Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders of Nanophase Technologies Corporation December [●], 2023 To Our Clients: Enclosed for your consideration are a prospectus (the “Prospectus”) wh |
|
| December 19, 2023 |
RIGHTS OFFERING BACKSTOP AGREEMENT Nanophase Technologies Corporation S-1/A Exhibit 10.69 RIGHTS OFFERING BACKSTOP AGREEMENT This Rights Offering Backstop Agreement (this “Agreement”) is dated as of November 13, 2023 and is by and among NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”), BRADFORD T. WHITMORE, an individual (“Whitmore”), GRACE INVESTMENTS, LP, a Delaware limited partnership (“Grace”), and STR |
|
| December 19, 2023 |
NANOPHASE TECHNOLOGIES CORPORATION BENEFICIAL OWNER ELECTION Nanophase Technologies Corporation S-1/A Exhibit 99.5 NANOPHASE TECHNOLOGIES CORPORATION BENEFICIAL OWNER ELECTION I (We), the beneficial owner(s) of shares of common stock, par value $0.01 per share (the “Common Stock”), of Nanophase Technologies Corporation (the “Company”), acknowledge receipt of your letter, the prospectus (the “Prospectus”) which forms a part of the Registration Statement on F |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 99.6 NANOPHASE TECHNOLOGIES CORPORATION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF SUBSCRIPTION RIGHTS NOMINEE HOLDER CERTIFICATION The undersigned, a bank, broker, trustee, depository or other nominee holder of subscription rights (the “Subscription Rights”) to purchase shares of common stock, par value $0.01 per share (“Common Stock”), of Na |
|
| December 19, 2023 |
Nanophase Technologies Corporation S-1/A Exhibit 99.1 FORM OF INSTRUCTIONS AS TO USE OF NANOPHASE TECHNOLOGIES CORPORATION SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE SUBSCRIPTION AND INFORMATION AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering by Nanophase Technologies Corporation, a Delaware corporation (“we,” “us,” “our,” or the “Company”), |
|
| November 29, 2023 |
United States securities and exchange commission logo November 29, 2023 Jess A. Jankowski President and Chief Executive Officer Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, Illinois 60446 Re: Nanophase Technologies Corporation Registration Statement on Form S-1 Filed November 21, 2023 File No. 333-275696 Dear Jess A. Jankowski: This is to advise you that we have not reviewed |
|
| November 21, 2023 |
Nanophase Technologies Corporation S-1 Exhibit 107.1 Calculation of Filing Fees Table Form S-1 (Form Type) Nanophase Technologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule or Carry Forward Rule Amount Registered(3) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Of |
|
| November 21, 2023 |
As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 Registration No. |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 16) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 5215 Old Orchard Road, Suite 620 Skokie, Illinois 60077 Telephone: (847) 733-1230 (Name, Addre |
|
| November 14, 2023 |
Nanophase Reports Third Quarter Results, New Financing Package EXHIBIT 99.1 Nanophase Reports Third Quarter Results, New Financing Package — Closed on $3.2 Million Financing — Delivered $29.3 Million in nine-month revenue — Won 2023 BeautyMatter NEXT Award — Named as finalist for 22nd annual Chicago Innovation Awards and 2024 Cosmetics & Toiletries Allē Awards ROMEOVILLE, Ill., Nov. 13, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: N |
|
| November 14, 2023 |
Nanophase Technologies Corporation 10-Q Exhibit 10.5 PROMISSORY NOTE (Bridge Note) Principal Amount: $2,000,000.00 Date of Note: November 13, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to STRANDLER, LLC, a South Dakota limited liability company (“Lender”), or order, in lawful money of the United States of America, the princi |
|
| November 14, 2023 |
Nanophase Technologies Corporation 10-Q Exhibit 10.4 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 |
|
| November 14, 2023 |
Nanophase Technologies Corporation 10-Q Exhibit 10.2 REPLACEMENT PROMISSORY NOTE (Revolving Note) Principal Amount: $5,200,000.00 Date of Note: November 13, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, |
|
| November 14, 2023 |
Nanophase Technologies Corporation 10-Q Exhibit 10.3 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( a |
|
| November 14, 2023 |
Nanophase Technologies Corporation 10-Q Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| August 2, 2023 |
Nanophase Reports Record Second Quarter Revenue EXHIBIT 99.1 Nanophase Reports Record Second Quarter Revenue — Delivered $11.9 Million in Q2 revenue — Product revenue up 10% in Q2 and 12% YOY — Profitable Quarter — Won Cosmopack Formulation Award at Cosmoprof North America ROMEOVILLE, Ill., Aug. 02, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care so |
|
| July 21, 2023 |
Mark E. Miller Joins Nanophase Board of Directors EXHIBIT 99.1 Mark E. Miller Joins Nanophase Board of Directors ROMEOVILLE, Ill., July 20, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — is pleased to annou |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 (July 19, 2023) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of I |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 11, 2023 |
Nanophase Reports Record First Quarter Revenue for 2023 EXHIBIT 99.1 Nanophase Reports Record First Quarter Revenue for 2023 — Delivered over $9 Million in Q1 revenue — Progressive bottom line improvement through Q1 ROMEOVILLE, Ill., May 11, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that |
|
| May 4, 2023 |
Nanophase Technologies Corporation 8-K Exhibit 10.1 PROMISSORY NOTE (Non-Revolving Note - TI) Principal Amount: $1,750,000.00 Date of Note: May 1, 2023 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, the princ |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 (May 4, 2023) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Employ |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| March 29, 2023 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2022) Nanophase Technologies Corporation 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2022) Name Jurisdiction of Formation Solésence, LLC Delaware |
|
| March 29, 2023 |
Nanophase Reports Third Consecutive Year of Record Revenue for 2022 EXHIBIT 99.1 Nanophase Reports Third Consecutive Year of Record Revenue for 2022 — Another record year with 27% YOY growth — Delivered $37 Million in full year revenue — In Beauty Science markets, Solésence revenue is up 27% YOY while Active Pharmaceutical Ingredients (API) sales are up 44% ROMEOVILLE, Ill., March 29, 2023 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a lead |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| March 29, 2023 |
Nanophase Technologies Corporation 10-K Exhibit 10.22 Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for conf |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) |
|
| November 8, 2022 |
Nanophase Reports Strong Revenue for Third Quarter as Growth Continues EXHIBIT 99.1 Nanophase Reports Strong Revenue for Third Quarter as Growth Continues ? Delivered $9.7 million in Q3 revenue???? ? In Beauty Science markets, Sol?sence revenue is up 39% YOY? ? In Personal Care Ingredients markets, Nanophase revenue is up 61% YOY? ROMEOVILLE, Ill., Nov. 08, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scient |
|
| September 8, 2022 |
Nanophase Files Complaint for Declaratory Judgment Nanophase Technologies Corp. 8-K Exhibit 99.1 FOR IMMEDIATE RELEASE? ? ? Nanophase Files Complaint for Declaratory Judgment Romeoville, Ill., Sept. 7, 2022 ? Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories ? with innovations that protect skin from environmental aggressors and aid |
|
| September 8, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 (August 31, 2022) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction |
|
| August 17, 2022 |
Nanophase Reports Record Revenue for Second Quarter as Growth Continues EXHIBIT 99.1 Nanophase Reports Record Revenue for Second Quarter as Growth Continues ? Delivered a record $11.2 million in Q2 revenue ? In Beauty Science markets, Sol?sence revenue is up 44% YOY while Active Pharmaceutical Ingredients (API) sales are up 79%? ROMEOVILLE, Ill., Aug. 17, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifi |
|
| August 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) |
|
| August 16, 2022 |
NT 10-Q 1 nanx-nt10q063022.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-22333 CUSIP NUMBER: 630079101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition R |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Technol |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Techno |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 11, 2022 |
Nanophase Reports Record Revenue for First Quarter as it Sets Stage for Strong Year EXHIBIT 99.1 Nanophase Reports Record Revenue for First Quarter as it Sets Stage for Strong Year ? Delivered a record $8.2 million in Q1 revenue ? In Beauty Science markets, Sol?sence revenue is up 29% YOY while Active Pharmaceutical Ingredients (API) sales are up 70%? ? Added key team members to support growth ROMEOVILLE, Ill., May 11, 2022 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (O |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) ( |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| March 31, 2022 |
EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Set Up For Strong Growth, Nanophase Reports Second Consecutive Year of Record Financial Results for 2021 as Solésence Continues to Lead and Personal Care Ingredients Category Thrives — Another record year with 70% YOY growth — Delivered $29 Million in full year revenue — In Beauty Science markets, Solésence revenue is up 170% YOY while Active Pharmac |
|
| March 31, 2022 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2021) NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2021) Name Jurisdiction of Formation Sol?sence, LLC Delaware |
|
| February 2, 2022 |
REPLACEMENT PROMISSORY NOTE (Revolving Note - AR) Nanophase Technologies Corporation 8-K Exhibit 10.4 REPLACEMENT PROMISSORY NOTE (Revolving Note - AR) Principal Amount: $8,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (?Lender?), or order, in lawful money of the United States of Ameri |
|
| February 2, 2022 |
PROMISSORY NOTE (Revolving Note - Inventory) Nanophase Technologies Corporation 8-K Exhibit 10.6 PROMISSORY NOTE (Revolving Note - Inventory) Principal Amount: $4,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (?Lender?), or order, in lawful money of the United States of America, t |
|
| February 2, 2022 |
Nanophase Technologies Corporation 8-K Exhibit 10.2 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and STRANDLER, LLC, a South Dakota limited liability company (?Lender?). PREAMBLE WHEREAS, Borrower desires to enter into certain secured financial transactions with Lender for t |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 (January 28, 2022) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction |
|
| February 2, 2022 |
Nanophase Technologies Corporation 8-K Exhibit 10.1 BUSINESS LOAN AGREEMENT THIS BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and BEACHCORP, LLC, a Delaware limited liability company (?Lender?). PREAMBLE WHEREAS, Borrower desires to enter into certain secured financial transactions with Lender for the f |
|
| February 2, 2022 |
AMENDED AND RESTATED BUSINESS LOAN AGREEMENT Nanophase Technologies Corporation 8-K Exhibit 10.3 AMENDED AND RESTATED BUSINESS LOAN AGREEMENT THIS AMENDED AND RESTATED BUSINESS LOAN AGREEMENT dated as of January 28, 2022 by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), and BEACHCORP, LLC, a Delaware limited liability company (?Lender?). The Agreement amends and restates, in its entirety, that certain Bu |
|
| February 2, 2022 |
Nanophase Technologies Corporation 8-K Exhibit 10.5 PROMISSORY NOTE (Term Note) Principal Amount: $1,000,000.00 Date of Note: January 28, 2022 PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?), hereby promises to pay to STRANDLER, LLC, a South Dakota limited liability company (?Lender?), or order, in lawful money of the United States of America, the principal |
|
| January 14, 2022 |
NANX / Nanophase Technologies Corporation / Conley John Howard Jr Passive Investment SC 13G/A 1 2021nanx.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2021 Check the appropriate box to designate the |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 1603 Orrington Ave., Suite 900 Evanston, Illinois 60201 Telephone: (847) 733-1230 (Name, Addre |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 (December 6, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission ( |
|
| December 9, 2021 |
STANDARD FORM INDUSTRIAL BUILDING LEASE Nanophase Technologies Corporation 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. STANDARD FORM INDUSTRIAL BUILDING LEASE 1. BASIC TERMS: This Section contains |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to to Commission File Number: 000-22333 Nanophase Te |
|
| November 3, 2021 |
Nanophase Technologies Reports Record Financial Results for Third Quarter Ended September 30, 2021 EXHIBIT 99.1 Nanophase Technologies Reports Record Financial Results for Third Quarter Ended September 30, 2021 Announces Another Record Quarter with 80% YOY Growth Delivered $22 Million in Nine-Month Revenue Sol?sence Nine-Month 2021 Revenue Exceeded Full Year 2020 Revenue by More Than 98% ROMEOVILLE, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leade |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22333 36-3687863 (State or Other Jurisdiction of Incorporation) |
|
| August 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (C |
|
| August 17, 2021 |
EXHIBIT 99.1 Nanophase Reports Record Second Quarter Financial Results as Sol?sence Beauty Science Growth Continues Announces 69% YOY Growth and $14M in Six-Month Revenue ROMEOVILLE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across various beauty and life science categories ? w |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 N |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 (August 10, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of |
|
| June 14, 2021 |
Nanophase Technologies Corporation 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE SUPPLY AGREEMENT THIS EXCLUSIVE SUPPLY AGREEMENT (?Agreement?), made |
|
| June 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 (June 8, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Emp |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 27, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 27, 2021 |
EXHIBIT 99.1 Nanophase Reports Record First Quarter Financial Results as Sol?sence Beauty Science Leads Growth Announces 75+% YOY Growth and $7M in Quarterly Revenue ROMEOVILLE, Ill., April 27, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically driven health care solutions across various beauty and life science categories ? with |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 (April 21, 2021) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS |
|
| April 21, 2021 |
FOURTH AMENDMENT TO BUSINESS LOAN AGREEMENT NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 FOURTH AMENDMENT TO BUSINESS LOAN AGREEMENT This Fourth Amendment is dated as of April 21, 2021 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (?Borrower?) in favor of BEACHCORP, LLC, a Delaware limited liability company (?Lender?) and amends that certain Business Loan Agreement dated as of November 19, 2018 ( as |
|
| April 20, 2021 |
As filed with the Securities and Exchange Commission on April 19, 2021 Registration No. |
|
| March 26, 2021 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2020) NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2020) Name Jurisdiction of Formation Sol?sence, LLC Delaware |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| March 11, 2021 |
EXHIBIT 99.1 Nanophase Reports Record 2020 Financial Results as Solésence Beauty Science and Life Science Materials Lead Growth Announces 35+% Overall Growth and $1M Profit ROMEOVILLE, Ill., March 11, 2021 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across various beauty and life science categorie |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 11, 2021 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2020 Check the appropriate box to designate the rule pursuant to which |
|
| December 23, 2020 |
NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 THIRD AMENDMENT TO BUSINESS LOAN AGREEMENT This Third Amendment is dated as of December 23, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of November 19, 2018 ( a |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 (December 23, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission |
|
| November 16, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn |
|
| November 13, 2020 |
nanx-def14a120920 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 1603 Orrington Ave., Suite 900 Evanston, Illinois 60201 Telephone: (847) 733-1230 (Name, Addre |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 (October 28, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or |
|
| November 3, 2020 |
EXHIBIT 99.1 Nanophase Reports Record Third Quarter 2020 Financial Results as Solésence Expands Beauty Footprint Announces 20+% Growth and Record Profitability ROMEOVILLE, Ill., Nov. 03, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across various beauty and life science categories, protecting |
|
| November 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 3, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 30, 2020 (October 28, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of I |
|
| October 30, 2020 |
Laura M. Beres Joins Nanophase Board of Directors as Solésence Expands Beauty Footprint EXHIBIT 99.1 Laura M. Beres Joins Nanophase Board of Directors as Solésence Expands Beauty Footprint ROMEOVILLE, Ill., Oct. 29, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care innovations across beauty and life science categories, is pleased to announce the appointment of Laura M. Beres to its Board of Direc |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 1603 Orrington Ave., Suite 900 Evanston, Illinois 60201 Telephone: (847) 733-1230 (Name, Addre |
|
| September 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 (September 16, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commissi |
|
| September 22, 2020 |
NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 SECOND AMENDMENT TO BUSINESS LOAN AGREEMENT This Second Amendment is dated as of September 8, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation ("Borrower") in favor of BEACHCORP, LLC, a Delaware limited liability company ("Lender") and amends that certain Business Loan Agreement dated as of November 19, 2018 ( |
|
| September 2, 2020 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 (August 25, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission ( |
|
| September 2, 2020 |
AMENDMENT #1 JOINT DEVELOPMENT & SUPPLY AGREEMENT NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 AMENDMENT #1 JOINT DEVELOPMENT & SUPPLY AGREEMENT This amendment #1 to the Amended and Restated Joint Development & Supply Agreement ("Agreement') is made this 25th day of August 2020 ("Effective Date") between COLORESCIENCE Inc., a company existing and organized under the laws of Delaware, ("COLORESCIENCE') with its principal place of business a |
|
| August 12, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi |
|
| August 6, 2020 |
EXHIBIT 99.1 Nanophase Reports Record Second Quarter 2020 Financial Results Announces 32% Growth for Quarter, 20% Year-Over-Year, Doubling of Formulated Product Sales and YTD Profitability ROMEOVILLE, Ill., Aug. 06, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environm |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 6, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog |
|
| May 13, 2020 |
Nanophase Technologies Corporation 10-Q Exhibit 10.2 LOAN AGREEMENT THIS LOAN AGREEMENT (“Agreement”) is made between Nanophase Technologies Corporation (“Borrower”), and Libertyville Bank & Trust Company, N.A. (“Lender”). The U.S. Small Business Administration (“SBA”) has authorized a guaranty (“Authorization”) of a loan from Lender to Borrower (“Loan”) having 2020 SBA Loan Number 31931171-00 whi |
|
| May 13, 2020 |
Nanophase Technologies Corporation 10-Q Exhibit 10.1 U.S. Small Business Administration PPP Loan Document Input Requirements SBA Loan# 31931171-00 SBA Loan Name Nanophase Technologies Corporation Approval Date Apr 08, 2020 SBA Loan App # Date of Documents Apr 16, 2020 Loan Amount 951,600.00 Loan Payment Amount (to the penny) 53,290.05 Lender Name Libertyville Bank & Trust Company, N.A. Lender Addr |
|
| April 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 29, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 29, 2020 |
EXHIBIT 99.1 Nanophase Reports First Quarter 2020 Financial Results Announces 8% Growth for Quarter, Outsized Formulated Product Sales ROMEOVILLE, Ill., April 29, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, tod |
|
| April 21, 2020 |
8-K 1 f8k042120.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 17, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-22333 36-3687863 (State or Other Jurisdict |
|
| April 21, 2020 |
Nanophase Receives Funding Under Paycheck Protection Program EXHIBIT 99.1 Nanophase Receives Funding Under Paycheck Protection Program ROMEOVILLE, Ill., April 21, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported that it received funding in the form of a loan un |
|
| March 31, 2020 |
Nanophase Reports 2019 Revenue Solésence Performs Well, First Half 2020 Outlook Positive EXHIBIT 99.1 Nanophase Reports 2019 Revenue Solésence Performs Well, First Half 2020 Outlook Positive ROMEOVILLE, Ill., March 31, 2020 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported financial results for |
|
| March 31, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2020 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 30, 2020 |
FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT Nanophase Technologies Corporation 10-K Exhibit 10.42 FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT This First Amendment is dated as of March 23, 2020 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of November 19, 2018 (“Lo |
|
| March 30, 2020 |
Nanophase Technologies Corporation 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| March 30, 2020 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2019) Nanophase Technologies Corporation 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2019) Name Jurisdiction of Formation Solesence, LLC Delaware |
|
| January 30, 2020 |
NANX / Nanophase Technologies Corp. / Conley John Howard Jr Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Nanophase Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 630079101 (CUSIP Number) (Date of Event which Requires Filing of this Statement) December 31, 2019 Check the appropriate box to designate the rule pursuant to which |
|
| January 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 (January 13, 2020) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission ( |
|
| December 4, 2019 |
8-K 1 nanx-8k120419.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2019 (December 3, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 3 |
|
| November 22, 2019 |
NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 NANOPHASE TECHNOLOGIES CORPORATION 2019 EQUITY COMPENSATION PLAN The purpose of the 2019 Nanophase Technologies Corporation Equity Compensation Plan (the “Plan”) is to provide designated employees of Nanophase Technologies Corporation (the “Company”) and its subsidiaries, and certain advisors, including non-employee members of the Board of Direct |
|
| November 22, 2019 |
NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 3.1 FOURTH AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF NANOPHASE TECHNOLOGIES CORPORATION Pursuant to the Certificate of Incorporation of Nanophase Technologies Corporation, as amended, and the Delaware General Corporation Law, the undersigned corporation, organized and existing under and by virtue of the Delaware General Corporation Law, hereby |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2019 (November 19, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission |
|
| November 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 1603 Orrington Ave., Suite 900 Evanston, Illinois 60201 Telephone: (847) 733-1230 (Name, Addre |
|
| November 14, 2019 |
NANX / Nanophase Technologies Corp. DEFA14A - - ADDITIONAL DEFINITIVE PROXY SOLITICING MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 14, 2019 |
EXHIBIT 99.1 Nanophase Reports Third Quarter 2019 Financial Results Announces 56% Growth for Year-Over-Year Formulated Product Sales The Company’s financial conference call is scheduled for November 15, 2019 at 4pm EST ROMEOVILLE, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for |
|
| November 14, 2019 |
Nanophase Technologies Corporation 10-Q Exhibit 4.3 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| November 14, 2019 |
Nanophase Technologies Corporation 10-Q Exhibit 4.2 COMMERCIAL SECURITY AGREEMENT THIS COMMERCIAL SECURITY AGREEMENT (“Agreement”) is dated as of November 20, 2019, and is made by NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“NTC”) and SOLÉSENCE, LLC, a Delaware limited liability company (“SLLC”), jointly and severally, in favor of BRADFORD T. WHITMORE (“Lender”). NTC and SLLC are r |
|
| November 14, 2019 |
Nanophase Technologies Corporation 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Techn |
|
| November 14, 2019 |
Nanophase Technologies Corporation 10-Q Exhibit 4.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (“Agreement”) dated as of November 13, 2019 by and between BRADFORD T. WHITMORE, an individual (“Whitmore” or “Purchaser”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (the “Company”). W I T N E S S E T H: WHEREAS, the Company, and its subsidiary, SOLÉSENCE, LLC, a Dela |
|
| October 17, 2019 |
NANX / Nanophase Technologies Corp. DEF 14A - - DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 7, 2019 |
NANX / Nanophase Technologies Corp. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 28, 2019 |
EXHIBIT 99.1 Nanophase Reports Second Quarter 2019 Financial Results Announces 150% Growth for Year-Over-Year Formulated Product Sales The company’s financial conference call is scheduled for August 29, 2019 at 11am EDT ROMEOVILLE, Ill., Aug. 28, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products fo |
|
| August 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 28, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2019 |
Nanophase Technologies Corporation 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technologi |
|
| August 2, 2019 |
NANOPHASE TECHNOLOGIES CORPORATION 8-K Exhibit 10.1 CERTAIN INFORMATION, MARKED IN THIS EXHIBIT WITH BRACKETS, HAS BEEN EXCLUDED FROM THIS EXHIBIT IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Joint Development Agreement This Joint Development Agreement (“Agreement”), da |
|
| August 2, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2019 (July 31, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS E |
|
| May 15, 2019 |
AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT Nanophase Technologies Corporation 10-Q Exhibit 10.1 AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT is entered into as of January 1, 2019 by and between BASF CORPORATION, a Delaware corporation (“BASF”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). RECITALS A. Nanophase and BASF (as successor-in-interest to Sun Sma |
|
| May 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11) Nanophase Technologies Corporation (Name of Issuer) COMMON STOCK, par value $.01 (Title of Class of Securities) 630079101 (CUSIP Number) Bradford T. Whitmore 1603 Orrington Ave., Suite 900 Evanston, Illinois 60201 Telephone: (847) 733-1230 (Name, Addre |
|
| May 15, 2019 |
Nanophase Technologies Corporation 10-Q Exhibit 4.1 NANOPHASE TECHNOLOGIES CORPORATION COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is made as of May 13, 2019 by and between Nanophase Technologies Corporation, a Delaware corporation with its principal office at 1319 Marquette Drive, Romeoville, Illinois 60446 (the “Company”), and Bradford T. Whitmore (the |
|
| May 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 15, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2019 |
EXHIBIT 99.1 Nanophase Reports First Quarter 2019 Financial Results Announces 30% Growth for Quarter and Strong Formulated Product Sales The company’s financial conference call is scheduled for May 16, 2019 at 11am EDT ROMEOVILLE, Ill., May 15, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for |
|
| May 15, 2019 |
Nanophase Technologies Corporation 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-22333 Nanophase Technolog |
|
| May 9, 2019 |
NANX / Nanophase Technologies Corp. CT ORDER begin 644 filename1 M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED%L@," P(#8Q,B W. |
|
| April 24, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS Em |
|
| April 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2019 (April 5, 2019) NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other (Commission (IRS E |
|
| April 11, 2019 |
Nanophase Technologies Corporation 8-K Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Separation Agreement and General Release (“Agreement”) is made between Mr. Jaime Escobar and Nanophase Technologies Corporation (“NTC”). Whereas, since March 26, 2018, Mr. Escobar has served as Chief Financial Officer of NTC pursuant to that certain employment agreement between Mr. Escob |
|
| April 4, 2019 |
NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 10.33 CHANGE IN TERMS AGREEMENT Borrower: Nanophase Technologies Corporation 1319 Marquette Drive Romeoville, IL 60446 Lender: Libertyville Bank and Trust Company 507 N. Milwaukee Ave Libertyville, IL 60048 (847) 367-6800 Principal Amount: $500,000.00 Date of Agreement: March 4, 2019 DESCRIPTION OF EXISTING INDEBTEDNESS. Promissory Note originally da |
|
| April 4, 2019 |
NANOPHASE TECHNOLOGIES CORPORATION 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-22333 NANOPHASE TECHNOLOGIES COR |
|
| April 4, 2019 |
BUSINESS LOAN AGREEMENT (ASSET BASED) NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 10.32 BUSINESS LOAN AGREEMENT (ASSET BASED) Borrower: Nanophase Technologies Corporation Lender: Libertyville Bank and Trust Company 1319 Marquette Drive 507 N. Milwaukee Ave Romeoville, IL 60446 Libertyville, IL 60048 (847) 367-6800 THIS BUSINESS LOAN AGREEMENT (ASSET BASED) dated March 4, 2019, is made and executed between Nanophase Technologies Co |
|
| April 4, 2019 |
SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2018) NANOPHASE TECHNOLOGIES CORPORATION 10-K Exhibit 21.1 SUBSIDIARY OF NANOPHASE TECHNOLOGIES CORPORATION (as of December 31, 2018) Name Jurisdiction of Formation Solesence, LLC Delaware |
|
| March 29, 2019 |
NANX / Nanophase Technologies Corp. NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-22333 CUSIP NUMBER: 630079101 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form |
|
| March 27, 2019 |
EXHIBIT 99.1 Nanophase Reports Record 2018 Revenue; Outlook for Solésence and Mineral UV Absorbers Strong The Company’s financial conference call is scheduled for March 28th at 11am EDT ROMEOVILLE, Ill., March 27, 2019 (GLOBE NEWSWIRE) - Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmen |
|
| March 27, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 27, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) DE 0-22333 36-3687863 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 15, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2019 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) (Co |
|
| March 15, 2019 |
AMENDMENT NO.4 TO ZINC OXIDE SUPPLY AGREEMENT Nanophase Technologies Corporation 8-K Exhibit 10.1 AMENDMENT NO.4 TO ZINC OXIDE SUPPLY AGREEMENT THIS AMENDMENT NO. 4 TO ZINC OXIDE SUPPLY AGREEMENT is entered into as of January 1, 2019 by and between BASF CORPORATION, a Delaware corporation (“BASF”) and NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Nanophase”). RECITALS A. Nanophase and BASF (as successor-in-interest to Sun Smart |
|
| December 4, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2018 NANOPHASE TECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-22333 36-3687863 (State or other jurisdiction of incorporation) ( |
